Page 193 - Ghidul Serviciilor Medicale Synevo, Ediția 1

Limite şi interferenŃe
7
VariaŃii intraindividuale: 3.6-12.4% .

Creşteri Scăderi
• efort fizic intens şi de durată, • consum moderat de • inaniŃie şi anorexie, • fumat, • stres şi boală recentă
alcool, • tratament cu insulină ; (IMA, AVC, intervenŃii chirurgicale, traumatisme),
4;7
• medicamente: cimetidină, ciclofenil, contraceptive • obezitate, • lipsa antrenamentului fizic,
orale, doxazosin, estrogeni, derivaŃi ai acidului fibric • hipertrigliceridemie ;
4;7
(clofibrat, gemfibrozil), lovastatin, pravastatin, • medicamente: androgeni, betablocante
simvastatin, acid nicotic, fenobarbital, fenitoin, (mai ales noncardioselective), acid
prazosin, terazosin, terbutalin, captopril, chenodeoxicolic, ciclosporină A,
carbamazepine, coenzima Q10, furosemid, insulină, ciproteron acetat (doze mari), danazol, diuretice,
ketoconazol, medroxiprogesteron, niacin, nifedipină, etretinat, interferon, interleukină, isotretinoin,
verapamil etc. 1;5;12 ; medroxiprogesteron, probucol, progestative,
• interferenŃe analitice: creşterea concentraŃiei tiazide 5;12 .
8
imunoglobulinelor determină o falsă creştere a HDL .

Bibliografie

1. Betteridge DJ. High Density Lipoprotein and Coronary Heart Disease. In BMJ 298(6679): 974-5. 1989. Ref Type: Journal (Full).
2. Cleeman JI. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evalution and Treatment of High Blood Cholesterol in Adults. In JAMA 285: 2486-97. 2001. Ref Type: Journal (Full).
3. Elena Popa Cristea. Metabolismul lipidelor. În Biochimie Medicala. Veronica Dinu, Eugen Trutia, Elena Popa-Cristea, Aurora Popescu,
Editura Medicală, România, 2 ed., 1998, 394-478.
4. Frances Fischbach. Chemistry Studies. În A Manual of Laboratory and Diagnostic Tests. Lippincott Williams & Wilkins, USA, 7 ed., 2004,
428-30.
5. Frances Fischbach. Effects of the Most Commonly Used Drugs on Frequently Ordered Laboratory Tests. In A Manual of Laboratory and
Diagnostic Tests. Lippincott Williams & Wilkins, USA, 7 ed., 2004, 1188-1238.
6. Gordon DJ, Rifkind BM. High Density Lipoprotein-the Clinical Implications of recent studies.In N Engl J Med 321(19): 1311-6. 1989. Ref
Type: Journal (Full).
7. Jacques Wallach. Boli metabolice şi ereditare. În Interpretarea testelor de diagnostic. Editura ŞtiinŃelor Medicale, Romania, 7 ed., 2001,
653-752.
8. Laborator Synevo. ReferinŃele specifice tehnologiei de lucru utilizate 2006. Ref Type: Catalog.
9. Laboratory Corporation of America. Directory of Services and Interpretive Guide. High-Density Lipoprotein Cholesterol. www.labcorp.com
2003. Ref Type: Internet Communication.
10. Maciejko JJ, Holmes DR, Kottke BA, et al. Apolipoprotein A-1 as a Marker of Angiographically Assessed Coronary-Artery Disease. In N
Engl J Med 309(7): 385-9. 1983. Ref Type: Journal (Full).
11. Miller NE. Association of High Density Lipoprotein Subclasses and Apolipoproteins with Ischemic Heart Disease and Coronary
Atherosclerosis. In Am Heart J 113(2 ): 587-97. 1987. Ref Type: Journal (Full).
12. Peter P Toth. The "Good Cholesterol", High-density Lipoprotein. In Circulation 111: 89-91. 2005. Ref Type: Journal (Full).